1,798 results match your criteria Psoriasis Pustular


Autoinflammatory keratinitzation diseases (AIKDs.

Actas Dermosifiliogr 2021 Jun 9. Epub 2021 Jun 9.

Servicio de Dermatología, Consorci Corporació Sanitària Parc Taulí, Universidad Autónoma de Barcelona, Spain.

Autoinflammatory keratinization disease (AiKD) is a novel clinical concept encompassing diseases with a genetic background and mixed pathogenic mechanisms of autoinflammation and autoimmunity, leading to an aberrant keratinization of the skin. Recent advances in medical genetics have revealed genetic causes and/or predisposing factors for a number of AiKD's, such as mutations in IL36RN related with pustular psoriasis, acrodermatitis continua and hidradenitis suppurativa, in CARD14 in pityriasis rubra pilaris type V and some forms of pustular psoriasis, and in NLRP1 related with familial keratosis lichenoides chronica (KLC). It is suspected that AiKD pathophysiology would also be involved in non-monogenic disorders. Read More

View Article and Full-Text PDF

Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan.

J Am Acad Dermatol 2021 Jun 8. Epub 2021 Jun 8.

Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.

Background: Because generalized pustular psoriasis (GPP) is uncommon, there are few studies reporting treatments and outcomes for large numbers of patients.

Objective: To report treatments and outcomes in a large cohort of hospitalized patients with GPP.

Methods: Using a Japanese national inpatient database, we identified 1516 patients with GPP who required hospitalization from July 2010 to March 2019. Read More

View Article and Full-Text PDF

Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy.

Expert Opin Biol Ther 2021 Jun 11. Epub 2021 Jun 11.

Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dermatologia, Rome, Italy.

Background: Information is limited from real-life studies evaluating the efficacy and safety of brodalumab.

Research Design And Methods: In this real-life study, we retrospectively examined a database of 90 patients with moderate-to-severe psoriasis treated with brodalumab (210 mg, s.c. Read More

View Article and Full-Text PDF

Tinea Incognito Mimicking Pustular Psoriasis in a Patient With Psoriasis and Cushing Syndrome.

Authors:
Gerhard Eichhoff

Cutis 2021 Apr;107(4):E30-E32

Dermatology Service Capital and Coast District Health Board, Wellington Regional Hospital, New Zealand.

View Article and Full-Text PDF

Management of Vipadika with Mahisha Gritha Padanimajjana - a case report.

J Complement Integr Med 2021 Jun 4. Epub 2021 Jun 4.

Department of Panchakarma, Amrita School of Ayurveda, Amrita Vishwa Vidyapeetham, Amritapuri, Kerala, India.

Objectives: Vipadika (Palmo plantar Psoriasis) is a Kshudra Kushta (minor skin disorder) of Vatakapha origin (body humors like vata and kapha) characterized by Sphutana (cracks) and Teevra Vedana (severe pain) in Pani (palm) and Pada (sole). Based on the symptoms it can be correlated to Palmo Plantar Psoriasis which is a variant of psoriasis which affects the skin of the palms and soles with the features of hyperkeratotic, pustular, or mixed morphologies. The treatment methods for Palmo plantor psoriasis causes severe side effects due to which an evident shift from modern treatments to ayurvedic treatment line. Read More

View Article and Full-Text PDF

A multi-center open-label study of apremilast in palmoplantar pustulosis (APLANTUS).

J Eur Acad Dermatol Venereol 2021 Jun 2. Epub 2021 Jun 2.

Department of Dermatology, University Medical Center Göttingen, Göttingen, Germany.

Background: Palmoplantar pustulosis (PPP) is a chronic skin disease with painful erythematous scaly or crusty lesions and pustules on the palms and soles. Apremilast is a phosphodiesterase 4 inhibitor that has proven effective in the therapy of psoriasis, psoriatic arthritis and in oral ulcers associated with Behcet's disease.

Objective: To explore the efficacy of apremilast in PPP. Read More

View Article and Full-Text PDF

Pustular Psoriasis and Associated Musculoskeletal Disorders.

J Rheumatol Suppl 2021 Jun;97:34-38

P.S. Helliwell, MD, PhD, Professor of Clinical Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Harehills Lane, Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, UK.

Pustular psoriasis (PsO) is an uncommon variant of PsO that may present in a generalized or localized fashion with or without musculoskeletal or systemic inflammatory involvement.Generalized pustular PsO (GPP) presents as a widespread acute or subacute pustular eruption that may be familial and is often associated with severe flares and systemic inflammation. The palmoplantar pustulosis variant is localized to palms and soles, whereas acrodermatitis continua of Hallopeau is localized to the nail apparatus. Read More

View Article and Full-Text PDF

Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

J Rheumatol Suppl 2021 Jun;97:1-3

L.V. McFarland, MS, PhD, Consultant, Public Health Reserves Corps, Seattle, Washington, USA.

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) held its annual meeting in 2020 in an online format due to travel restrictions during the coronavirus disease 2019 (COVID-19; caused by SARS-CoV-2) pandemic. The virtual meeting was attended by 351 rheumatologists, dermatologists, representatives of biopharmaceutical companies, and patient research partners. Similar to previous years, GRAPPA's annual meeting focused on the 3 overlapping missions of education, research, and clinical care of psoriatic disease. Read More

View Article and Full-Text PDF

Recalcitrant paradoxical pustular psoriasis induced by infliximab: Two case reports.

World J Clin Cases 2021 May;9(15):3655-3661

Department of Dermatology, Midwest Center for Dermatology and Cosmetic Surgery, Clinton Township, MI 48038, United States.

Background: Paradoxical psoriasis induced by tumor necrosis factor alpha antagonists is a rare side effect of those drugs and has similarities with and differences from classical psoriasis in clinical and pathological characteristics. Treating severe paradoxical psoriasis is challenging because the reported cases are rare, with treatment experience being only anecdotal.

Case Summary: We report 2 cases of paradoxical psoriasis caused by infliximab. Read More

View Article and Full-Text PDF

Ixekizumab-induced paradoxical pustular reaction successfully treated with guselkumab.

Clin Exp Dermatol 2021 May 24. Epub 2021 May 24.

Department of dermatovenerology, Clinical Hospital Centre Rijeka.

Targeted biologics have been successfully used for the treatment of moderate to severe psoriasis . However, in parallel to the increasing use of biological agents, the number of paradoxical adverse events (PAEs) is increasing as well . Herein, we report a case of a palmoplantar pustular reaction in a patient with severe psoriasis treated with ixekizumab. Read More

View Article and Full-Text PDF

Clinical analysis of generalized pustular psoriasis in Chinese patients: A retrospective study of 110 patients.

J Dermatol 2021 May 21. Epub 2021 May 21.

Department of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.

Generalized pustular psoriasis is an immune-mediated dermatologic condition characterized by widespread, sterile, subcorneal pustules. However, limited information exists regarding the clinical course of generalized pustular psoriasis. This study aimed to examine the precipitating factors, clinical manifestations, laboratory data, relapse patterns, and prognosis of generalized pustular psoriasis at our hospital and to improve the diagnosis and treatment. Read More

View Article and Full-Text PDF

Psoriasis: a brief overview.

Clin Med (Lond) 2021 05;21(3):170-173

St John's Institute of Dermatology, London, UK

Psoriasis is a clinically heterogeneous lifelong skin disease that presents in multiple forms such as plaque, flexural, guttate, pustular or erythrodermic. An estimated 60 million people have psoriasis worldwide, with 1.52% of the general population affected in the UK. Read More

View Article and Full-Text PDF

Infantile pustular psoriasis: Case report of successful treatment with acitretin in a 4-week-old infant.

JAAD Case Rep 2021 May 1;11:121-123. Epub 2021 Apr 1.

UCSF Dermatopathology and Oral Pathology Service, San Francisco, California.

View Article and Full-Text PDF

Clinical and trichoscopic features in various forms of scalp psoriasis.

J Eur Acad Dermatol Venereol 2021 May 15. Epub 2021 May 15.

Dermatology -IRCCS Policlinico di Sant'Orsola - Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum University of Bologna, Bologna, Italy.

Background: Scalp psoriasis is often undiagnosed or inadequately treated. The patient himself underestimates the seriousness of this hair disease and consults too late to a dermatologist.

Objectives: The aim of our study was to create a correlation between the clinical patterns and trichoscopy of scalp psoriasis such in a way to help the clinician to make the diagnosis and select the appropriate therapy. Read More

View Article and Full-Text PDF

Treatment of Generalized Pustular Psoriasis of Pregnancy With Infliximab.

Cutis 2021 Mar;107(3):E2-E5

Dr. Beksac is from the Department of Dermatology, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey. Dr. Adisen is from and Dr. Gurer was from the Department of Dermatology, Gazi University Faculty of Medicine, Ankara, Turkey.

Generalized pustular psoriasis of pregnancy (GPPP) is a rare and severe condition that may impair the health of the mother and fetus. Effective treatment is essential, as treatment options for GPPP are limited due to concerns about unfavorable pregnancy outcomes. We report the case of a 22-year-old woman with GPPP that was unresponsive to systemic corticosteroids. Read More

View Article and Full-Text PDF

An update on genetic basis of generalized pustular psoriasis (Review).

Int J Mol Med 2021 Jun 6;47(6). Epub 2021 May 6.

Department of Laboratory Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.

Generalized pustular psoriasis (GPP) is a rare and severe auto‑inflammatory skin disease that is characterized by recurrent, acute onset, and generalized pustular eruptions on erythematous, inflamed skin. GPP is traditionally classified as a variant of psoriasis vulgaris, even though recent clinical, histological and genetic evidence suggests that it is a heterogeneous disease and requires a separate diagnosis. In recent years, variants of , , and genes have been identified as causative or contributing to genetic defects in a proportion of patients affected by GPP. Read More

View Article and Full-Text PDF

Acrodermatitis Continua of Hallopeau Evolving into Generalized Pustular Psoriasis Following COVID-19: A Case Report of a Successful Treatment with Infliximab in Combination with Acitretin.

Biologics 2021 27;15:107-113. Epub 2021 Apr 27.

Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, Poland.

The global pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging. Various cutaneous manifestations have been observed in patients with SARS-CoV-2 infection, yet exacerbations of psoriasis have been reported sporadically. Acrodermatitis continua of Hallopeau (ACH) is an uncommon, sterile pustular dermatosis involving one or more digits. Read More

View Article and Full-Text PDF

Generalized annular pustular psoriasis (Milian-Katchoura type) induced by systemic steroids.

Clin Case Rep 2021 Apr 20;9(4):2507-2509. Epub 2021 Mar 20.

Department of Dermatology Cheikh Khalifa International Hospital University Mohamed IV of Health Sciences Casablanca Morocco.

The aim of my clinical image is to recall this rare and benign form of pustular psoriasis and to insist on the role of the triggers of pustular psoriasis, mainly the drugs. Read More

View Article and Full-Text PDF

Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease.

Int J Mol Sci 2021 Apr 21;22(9). Epub 2021 Apr 21.

Dermatology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.

Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory responses involved in pustular psoriasis. Read More

View Article and Full-Text PDF

Early psoriatic arthritis in Japan: Post-hoc analyses from a survey by the Japanese Society of Psoriasis Research.

J Dermatol 2021 Jun 25;48(6):902-906. Epub 2021 Apr 25.

Department of Dermatology, Kinki University Faculty of Medicine, Osaka, Japan.

To determine the characteristics of the early phase of psoriatic arthritis (PsA), we conducted a subanalysis of a retrospective survey of Japanese patients. In this study, we enrolled patients with early onset within either 2 years or 1 year from onset among the 1282 patients with PsA that had previously been reported. Among the total reported PsA patients, 304 (23. Read More

View Article and Full-Text PDF

Delayed diagnosis of holocarboxylase synthetase deficiency in three patients with prominent skin findings.

Pediatr Dermatol 2021 Apr 19. Epub 2021 Apr 19.

Department of Pathology and Laboratory Medicine, Children's Mercy Hospital, Kansas City, MO, USA.

Holocarboxylase deficiency (HLCSD) is caused by biallelic pathogenic variants in HLCS and is associated with poor feeding, emesis, lethargy, seizures, life-threatening metabolic acidosis, and hyperammonemia. Skin involvement in HLCSD is typically described as scaly, erythrodermic, seborrhea-like, or ichthyosiform, but there is a paucity of reports. We report three patients, including two siblings, with HLCSD and significant cutaneous manifestations including ichthyosiform dermatitis and a presentation with features of annular pustular psoriasis. Read More

View Article and Full-Text PDF

Psoriasis characteristics for the early detection of psoriatic arthritis.

J Rheumatol 2021 Apr 15. Epub 2021 Apr 15.

School of Medicine, University of Utah, Salt Lake City, Utah, United States of America; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States of America; Wellcome Sanger Institute, University of Cambridge, Hinxton, United Kingdom. Address correspondence to Bing-Jian Feng, Mail: 30 N 1900 E, Department of Dermatology, Salt Lake City, UT 84108, USA. Email:

Objective: Delays in the diagnosis and treatment of psoriatic arthritis (PsA) are common. These delays contribute to impairments in quality of life and joint damage. This study aims to calculate the incidence rate of PsA over time and identify clinical features that may be used for PsA prediction in psoriasis patients. Read More

View Article and Full-Text PDF

Psoriasis.

Lancet 2021 Apr;397(10281):1301-1315

St John's Institute of Dermatology, Faculty of Life Sciences and Medicine, King's College London, London, UK.

Psoriasis is a common, chronic papulosquamous skin disease occurring worldwide, presenting at any age, and leading to a substantial burden for individuals and society. It is associated with several important medical conditions, including depression, psoriatic arthritis, and cardiometabolic syndrome. Its most common form, chronic plaque or psoriasis vulgaris, is a consequence of genetic susceptibility, particularly in the presence of the HLA-C*06:02 risk allele, and of environmental triggers such as streptococcal infection, stress, smoking, obesity, and alcohol consumption. Read More

View Article and Full-Text PDF

Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare.

BMJ Open 2021 03 30;11(3):e043666. Epub 2021 Mar 30.

Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, Paris, France

Introduction: Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening disease characterised by recurrent flares of widespread neutrophilic aseptic skin pustular eruption. Despite the availability of approved biologics for GPP in Japan, Taiwan and Thailand, associated evidence is largely based on uncontrolled studies in which acute flares were not directly assessed. Therefore, there is a high unmet need to investigate new rapid-acting effective treatments that resolve symptoms associated with acute GPP flares. Read More

View Article and Full-Text PDF

Perspectives on the pharmacological management of psoriasis in pediatric and adolescent patients.

Expert Rev Clin Pharmacol 2021 Apr 22:1-13. Epub 2021 Apr 22.

Service De Dermatologie Et Médecine Vasculaire, Hôpital Victor Dupouy, Argenteuil, France.

Introduction: Psoriasis affects about 0.5% of children and adolescents, it has a high impact of social life. Management can be difficult. Read More

View Article and Full-Text PDF

Pustular Psoriasis and Associated Musculoskeletal Disorders.

J Rheumatol 2021 Mar 15. Epub 2021 Mar 15.

As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; H. Bachelez, MD, PhD, Department of Dermatology, Hôpital Saint-Louis, AP-HP, and Laboratory of Genetic Skin Diseases, Imagine Institute, Université de Paris, Paris, France; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/ Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; C. Rosen, Division of Dermatology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada; A. Garg, MD, Chair, Department of Dermatology, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA; E. Zudak, BFA, Vice President, Strategic Partnerships, WCG Trifecta, Indianapolis, Indiana, USA; O. Elkayam, MD, V. Furer, MD, Rheumatology Department, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; J.F. Merola, MD, MMSc, Harvard Medical School, Brigham and Women's Hospital, Department of Dermatology and Department of Medicine, Division of Rheumatology and Immunology, Boston, Massachusetts, USA; J. Chau, GRAPPA Patient Research Partner, Hong Kong; M. Kishimoto, MD, Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan; P.S. Helliwell, MD, PhD, Professor of Clinical Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Harehills Lane, Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, UK. KCD received grants/is an investigator for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer Ingelheim; is on the speakers bureau for Novartis (nonpromotional only); and is a consultant/on the advisory board for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Ortho Dermatologic, and Boehringer Ingelheim. PJM received research grants, consultation fees, and/or speaker honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, and UCB. AG received grants/is an investigator for the National Psoriasis Foundation, UCB, Incyte; and is a consultant/on the advisory board for AbbVie, Amgen, Asana Biosciences, Bristol Myers Squibb, Boehringer Ingelheim, Incyte, Janssen, Pfizer, UCB, and Viela Biosciences. JFM is consultant and/or investigator for Merck, Bristol Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and Leo Pharma. MK receives consulting fees and/or honoraria from AbbVie, Amgen-Astellas BioPharma, Asahi-Kasei Pharma, Astellas, Ayumi Pharma, BMS, Celgene, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono Pharma, Pfizer, Tanabe-Mitsubishi, Teijin Pharma, and UCB Pharma. OE receives consulting fees or honoraria from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Roche, Pfizer, Boehringer Ingelheim, and Novartis. This paper does not require institutional review board approval. Address correspondence to Dr. K. Callis Duffin, University of Utah, 4A330 Dermatology, SOM, 30 North 1900 East, Salt Lake City, UT 84132, USA. Email:

Pustular psoriasis (PsO) is an uncommon variant of PsO that may present in a generalized or localized fashion with or without musculoskeletal or systemic inflammatory involvement. Generalized pustular PsO (GPP) presents as a widespread acute or subacute pustular eruption that may be familial and is often associated with severe flares and systemic inflammation. The palmoplantar pustulosis variant is localized to palms and soles, whereas acrodermatitis continua of Hallopeau is localized to the nail apparatus. Read More

View Article and Full-Text PDF